BIOCOM Event

11th Berlin Conference on Life Sciences

Novel Antimicrobials and AMR Diagnostics

2 March 2018, Fraunhofer Forum, Berlin, Germany

Sponsors:

BOEHMERT & BOEHMERT

FLANDERS INVESTMENT & TRADE

Supporting Partners:

Fraunhofer

BEAM Alliance

British Embassy Berlin

ND4BB ENABLE

European Biotechnology NETWORK

Media Partner:

European Biotechnology Life Sciences and Industry Magazine

BIOCOM AG

Wanted: Novel Antimicrobials and AMR Diagnostics

How to bring novel antimicrobials and diagnostics from lab to market? How to finance risky clinical development? Which regulatory frameworks do exist for new antibiotics and diagnostics? Which incentives support business models best? Small and medium-sized enterprises (SMEs) constitute the major innovation engine in the AMR arena with significant pipelines of novel antimicrobials and diagnostics targeting multidrug-resistant bacteria. Although European biotech companies with AMR activities raised more than €200m in 2017, sustainable business models and market prospects are still challenging.

At the same time, a series of global initiatives were started: the Interagency Consultative Group (IACG) established by the United Nations; the Global R&D Hub resulting from the 2017 G20 summit; international multimillion-euro funding bodies such as CARB-X and the Global Antibiotic Research and Development Partnership (GARDP); the AMR Call to Action initiative, and the InnoFin Infectious Disease program financed by the European Investment Bank. These initiatives are particularly welcomed by SMEs; however, they call for implementing further supportive instruments.

Against this background, BIOCOM AG and the European SME organization BEAM Alliance are pleased to invite key players in the AMR field to join the "11th Berlin Conference on Life Sciences – Novel Antimicrobials & AMR Diagnostics" and to establish a discussion platform highlighting the challenges particularly related to SMEs.

Several sessions with 50 top-class speakers will cover all the different aspects of AMR therapeutic and diagnostics development, financing and market access. Drug developers, diagnostic experts and microbiologists from European businesses as well as researchers, entrepreneurs, market specialists, investors and start-ups will shed light on this challenging field.

BEAM Alliance Position Paper 2017

Key Guidelines to implement effective measures toward SMEs to revive the antibacterial R&D field

2017 marks the beginning of the most collective fight ever against the superbug threat. All over the world – be it on the local, the national and the international level – important initiatives have been started to address the challenge of antimicrobial resistance (AMR) and to spend substantial amounts of funding to bring forward research and development (R&D) in the field. The long-term success of these measures will depend on whether stakeholders are able to integrate the perspectives of small and medium-sized enterprises (SMEs). With the largest pipeline of innovative products, SMEs are the major innovation engine in the AMR field to provide patients with effective drugs in the fight against AMR. However, to ultimately revive antibacterial R&D, further specific support of SME-driven innovation is key.

Strong need for further action to revive antibacterial R&D

The existing initiatives demonstrate that longtime warning of microbiologists and health care professionals is now heard. From now the world is acting on many fronts. However, bacteria are evolving resistances faster than policy makers are implementing actions. Even in European and in Northern American hospitals, the rise of AMR leaves patients with no treatment option; back to the Pre-Penicillin era.

This is because of the versatile properties of bacteria to exchange genetic materials, to adapt their metabolism almost instantaneously in case of threat and to find compensatory survival mechanisms, thus easily outpacing human efforts to control them. From this background, it is of enormous importance to ultimately revive R&D in AMR by developing compelling surveillance data, encouraging out-of-the-box thinking, rewarding R&D evidence, strengthening existing scientific expertise, further developing scientific capacities and enlarging infrastructure on the national and international level. Only these strategies will provide innovative, effective and sustainable treatments for AMR patients worldwide.

New measures to support SMEs for being the crucial innovation engine in the AMR arena

Today, the antibacterial therapeutic area is recognised to be the most underserved segment of the pharmaceutical industry. Only very few large pharmaceutical corporations are actively involved in innovative R&D efforts. However, there are about 250 biotech companies worldwide who are mainly focusing on antimicrobial drug development to bring novel therapies from bench to bedside. As a matter of fact, **biotech companies constitute the crucial innovation engine in the AMR arena with the most significant pipeline of new antibiotics or novel antimicrobials as alternative treatments**.

In numbers, members of the BEAM Alliance together contribute over 120 potential new antibiotic compounds or curative and preventive technologies to this pipeline. Of these, a majority target critical pathogens as mentioned by the WHO priority list and approximately 30% investigate new mechanisms of actions or new targets, thus representing a high diversity of innovative approaches to fight AMR. The SMEs in the BEAM alliance also represented half of the signatories of the “Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance” which was launched at the World Economic Forum in Davos, Switzerland, in 2016.

From a European perspective, BEAM is convinced, that a call to action from policymakers is not enough to counter act the current situation. While this certainly gives hope to all parties invested in the cause to stop superbugs, it did not reach yet the inflection point that would give the confidence to private investors to revive investment in the R&D field.

To advocate re-investing in the field, we need to implement new measures that ultimately translate into achievements for existing players in the field and inspire new ones. **BEAM members propose herein a series of guidelines to help ensure that the current collective effort made by policymakers, foundations, international organisations and others is effectively targeting the needs of SMEs in the biotech sector.**

SME-driven innovation in the AMR R&D field is key for future success. For this reason, we describe herein 10 recommendations to support our needs:

1. Adequately-shaped incentive mechanisms that ultimately rewards R&D evidence
2. Health Technology Assessment recognising the true value of SME innovation
3. Dedicated regulatory pathways to support the specific needs of AMR projects and act as pre-qualification criteria to some PUSH/PULL incentive mechanisms
4. PUSH incentives and funding mechanisms that are directed to SMEs, calibrated and accessible for SMEs in practice
5. Calibrated Market Entry Rewards (MER) to ensure continuous and sustainable innovation from academics to biotech companies and to large pharma players
6. R&D prizes and phase entry rewards as effective PULL mechanisms for SMEs to incentivise the most underserved indications in AMR
7. Targeted tax incentives specifically addressing SMEs to incentivise private investments into AMR-focused companies and/or avoid de-prioritization
8. Going beyond to exploit all possibilities for AMR from SMEs
9. Support education to strengthen attractiveness of the field for R&D professionals/scientists
10. Long term thinking and wisely usage of AMR innovations combined with appropriate diagnostics development

About BEAM Alliance: The BEAM Alliance (Biopharmaceutical companies from Europe innovating in Anti-Microbial resistance research) plays a key role working on a European and national level to represent the interests of its 40 members. The BEAM members are collectively developing more than 100 new compounds focused upon the cure and prevention of bacterial infections. They cover the whole range of pharmaceutical drug development from small molecule antibiotics, antibiotic combinations, phages, antibodies, prophylactic and therapeutic vaccines, peptides, prebiotics, other bioproducts, adjunctive therapies and medical devices, thus representing the large majority of all European companies actively working on AMR. The goal of the BEAM alliance is to maintain and promote awareness of SME-driven innovation in the field and to support policymakers in understanding economic business models around AMR. The BEAM Alliance closely cooperates with all stakeholders dedicated to the fight against AMR.

BEAM Alliance full members & international members*

Abac Therapeutics · AiCuris Anti-infective Cures · Alaxia · Allecra Therapeutics · Antabio · AntibioTx · Arsanis · Auspherix · Basilea Pharmaceutica International · BioFilm Pharma · BioVersys · Centauri Therapeutics · Combioxin · Da Volterra · Debiopharm International · Deinobiotics/Deinove · Destiny Pharma · Discuva/Summit · Eligo Bioscience · Fastinov · Gedea Biotech AB · Helperby Therapeutics · Hypharm GmbH · Immunethep · Karveel Pharmaceuticals · MaaT Pharma · Madam Therapeutics · Motif Bio · Mutabilis · Nabriva Therapeutics · Neem Biotech · Northern Antibiotics · Nosopharm · NovaBiotics · Omnix Medical · Pherecydes Pharma · Phico Therapeutics · Polyphor · QureTech Bio · Redx Anti-Infectives · Septeos · SetLance srl · Ultupharma · VaxDyn

BEAM Alliance associated members*

Bioaster – Vivexia – Vibiosphen - AMR centre

*as of. Feb 16, 2018

www.beam-alliance.eu

Programme

Opening & Plenary Session | Room Spectrum — Page 11

Opening Session

8:45 Introduction

8:50 Welcome Address
Prof. Dr. Frank Emmrich, Fraunhofer Institute for Cell Therapy and Immunology IZI, DE

9:00 Setting the scene
Dr. Marc Gitzinger (session chair), Bioversys AG, CH

Plenary Session

Keynotes

9:10 Addressing drug-resistant infections: a global and collaborative endeavour
Jean-Pierre Paccaud, PhD, Global Antibiotic R&D Partnership (GARDP), CH

9:30 Feeding the AMR pipeline through innovation – challenges and solutions for European SMEs
Mark Jones, PhD, Basilea Pharmaceutica Ltd., CH

9:50 Replenishing and enabling the pipeline for anti-infective resistance
Aleks Engel, PhD, Novo Holdings Repair Impact Fund, DK
Prof. George E Griffin, PhD, St. George's, University of London, UK

10:10 The challenge of bringing successful AMR diagnostics to the clinic
Jorge Villacian, MD, Janssen Diagnostics, Janssen Pharmaceutical R&D, Johnson & Johnson, BE

10:30 Coffee break with posters & exhibition

Session 1: Market access in the era of AMR – from idea to product | Room Spectrum — Page 14

11:00 The patent perspective: How to protect IP in a field of multiple public, private and public/private collaborations?
Dr. Markus Engelhard (session chair)
BOEHMERT & BOEHMERT, DE

11:15 A new breakthrough class of Gram-negative antibiotics
Dr. Glenn Dale, Polyphor Ltd., CH

11:30 Panel discussion:
"Efficacy evaluation for novel antimicrobial approaches: current challenges and new routes"
Dr. Nicolas Tesse (panel moderator) SEPTEOS SAS, FRE
Guennaëlle Dieppois, PhD Debiopharm Int. SA, CH
Dr. Glenn Dale Polyphor Ltd., CH
Prof. Dr. Johan W. Mouton Erasmus University Rotterdam, NL

12:00 Accelerating diagnostics use to prevent AMR on a global level
Dr. Catharina Boehme, FIND Diagnostics, CH

12:15 Sustainable economic models to revitalise antibiotic development – lessons learned from DRIVE-AB
Dr. Christine Årdal, Norwegian Institute of Public Health, NO

12:30 Panel discussion:
How to bring AMR innovation to the market
Dr. Christine Årdal (panel moderator), Norwegian Institute of Public Health, NO
Prof. Anders Karlén, PhD, Uppsala University, SE
Ghada Zoubiane, PhD, Wellcome Trust, UK

Session 2: From basic research to market – recent academic anti-infective and diagnostis innovations | Room Forum — Page 15

11:00 Is AMR becoming the greatest challenge in global public health?
Dr. Jan Wauters, Flanders Investment & Trade, Government of Flanders, US

11:10 The value of academic research in AMR innovations
Prof. Herman Goossens, MD, University of Antwerp, BE

11:25 Tackling AMR via innovative natural products
Prof. Dr. Rolf Müller, Helmholtz Institute/German Center for Infection Research (DZIF), DE

11:40 First clinical results of cold plasma treated chronic infected wounds
Dr. Kai Masur, Leibniz Institute for Plasma Science and Technology, DE

11:55 Identification of novel antimicrobials using cell-free systems
Dr. Stefan Kubick, Fraunhofer Institute, DE

12:10 Antibiotics research at the Institut Pasteur in Paris and in the Institut Pasteur International Network
Dr. Philippe Glaser, Institut Pasteur, FR

12:25 Diagnostic tools to distinguish between bacterial and viral infections to reduce antibiotic abuse
Prof. Per Venge, MD PhD, Uppsala University, SE

12:40 Rapid diagnostics – from barriers to solutions for AMR
Dr. Till Bachmann, University of Edinburgh, UK

12:55 Lunch break with posters & exhibition

Programme

Session 3: Technology highlights and challenges – novel antimicrobials | Room Spectrum — Page 18

13:50 Introduction: The value of SMEs in AMR innovations
Marie Petit (session chair), BEAM Alliance, FR

14:00 Priority setting for R&D of new antibiotics – the WHO perspective
Sarah Paulin, PhD, World Health Organization, CH

14:15 Fostering investment in AMR innovation – the UNCTAD World Investment Forum 2018
Christoph Spennemann, UNCTAD, CH

14:30 The need for coordination: the global AMR R&D hub
Andrea Spelberg,
Federal Ministry of Education and Research, DE

14:40 Insights into the development of anti-infective therapies in AMR dedicated SMEs in Europe

The development of a synthetic branched peptide for fighting multi-resistant Gram-negative bacteria
Prof. Alessandro Pini, PhD, SetLance srl, IT

Six birds by two stones – the development of ASN100, a monoclonal antibody product candidate targeting Staphylococcus aureus
Zoltán Magyarics, MD, PhD, Arsanis Inc., US/AT

Artilysin® – an intelligent platform technology to combat MDR pathogens
Martin Grießl, Lysando AG, DE

15:10 Leveraging technology to spur antibiotic discovery
Dr. Mariana Vaschetto, Collaborative Drug Discovery Inc., UK

Session 4: Technology highlights and challenges – diagnostics | Room Forum — Page 19

13:50 Platforms, biomarkers, data: an industry perspective on molecular microbiology
Dr. Achim Plum, Curetis N.V., DE

14:05 Bringing photonics to the clinic: concept for an user-open center for photonics in infection research
Prof. Dr. Jürgen Popp, Leibniz Institute of Photonic Technology e.V., DE

14:20 Rapid tests to detect antibiotic resistance
Bruce Savage, GFC Diagnostics, UK

14:35 Development of diagnostics for antimicrobial resistance – a company perspective
Dr. Ralf Ehricht, Abbott (former Alere Technologies GmbH), DE

14:50 Pulse Controlled Amplification: A platform technology for ultrafast AMR diagnostics and beyond
Dr. Lars Ullerich, GNA Biosolutions GmbH, DE

15:05 Concept ≠ Technology ≠ Product. What it takes to create an actionable Dx in the fight against AMR
Kfir Oved, PhD, MD, MeMed Diagnostics Ltd

15:25 Coffee break with posters & exhibition

Closing Session | Room Spectrum

16:00 Start-up pitch — Page 22

Oppilotech Ltd, London, UK
Vaxdyn S.L., Seville/Madrid, ES
AGILeBiotics B.V., Groningen, NL
SpinDiag GmbH, Freiburg, DE
PhagoMed Biopharma GmbH, Vienna, AT
Resistell, Basel, CH
FASTinov AS, Porto, PT

16:45 Investors talk: Which business models are worth to invest? — Page 26

Henri-François Boedt, European Investment Bank, LU
Prof. Kevin Outterson, CARB-X, US
Dr. med. Beat Steffen, Novartis Venture Fund, CH
Dr. Peter Jackson, AMR Centre Ltd, UK
Emmanuelle Coutanceau, Novo Seeds, Novo Holdings A/S, DK
Aleks Engel, Novo Holdings Repair Impact Fund, DK

17:15 Start-up ceremony

17:20 Market place & networking

19:00 End of the day

Poster list see page 30

Fraunhofer
LIFE SCIENCES

FRAUNHOFER GROUP FOR LIFE SCIENCES



THE FRAUNHOFER GROUP FOR LIFE SCIENCES

Fraunhofer Group for Life Sciences

Nikolai-Fuchs-Str. 1
Main entrance: Stadtfelddamm
30625 Hannover
Germany

Chairman of the Fraunhofer Group for Life Sciences and Director of the Fraunhofer Institute for Process Engineering and Packaging IVV:

Prof. Dr. Horst-Christian Langowski

Contact

Head of Central Office:
Dr. Claus-Dieter Kroggel
Phone +49 511 5350-449
Fax +49 511 5350-155
claus.kroggel@vls.fraunhofer.de

www.lifesciences.fraunhofer.de

Six Fraunhofer Institutes and a Fraunhofer research institution, each having proven in-depth expertise in different areas within the life sciences, are involved in this Group: the Fraunhofer Institutes for Biomedical Engineering IBMT, Interfacial Engineering and Biotechnology IGB, Molecular Biology and Applied Ecology IME, Toxicology and Experimental Medicine ITEM, Process Engineering and Packaging IVV, Cell Therapy and Immunology IZI, and the Fraunhofer Research Institution for Marine Biotechnology and Cell Technology EMB. Their combined knowledge of biology, chemistry, biochemistry, biotechnology, medicine, pharmacology, ecology, and nutritional science is thus pooled and synergized within this Fraunhofer Group. In all these Fraunhofer Institutions, the scientists collaborate in interdisciplinary teams, so that tailored know-how concerning information technology, engineering science, and legal requirements is also available. Research and implementation at the client's facilities therefore go hand in hand.

The Fraunhofer-Gesellschaft stands for reliable partnership in applied research. As the largest research organization of its kind in Europe, it develops market-oriented solutions tailored to the specific requirements of each client. A solid basis for this is its own pre-competitive research, geared to the basics and frequently undertaken in close cooperation with universities and other academic institutions.

One of the most important things we have learned: the path from the first idea to the perfect solution is always very exciting – and we will gladly go down this path with you.

THE SYNERGISTS

Institutes of the Group

Fraunhofer Institute for Biomedical Engineering IBMT
Joseph-von-Fraunhofer-Weg 1
66280 Sulzbach, Germany
Phone +49 6897 9071-100
info@ibmt.fraunhofer.de

Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB
Nobelstrasse 12
70569 Stuttgart, Germany
Phone +49 711 970-4401
info@igb.fraunhofer.de

Fraunhofer Institute for Molecular Biology and Applied Ecology IME
Forckenbeckstr. 6
52074 Aachen, Germany
Phone +49 241 6085-0
Phone +49 69 6301-7620
info@ime.fraunhofer.de

Division Applied Ecology and Bioresources
Auf dem Aberg 1
57392 Schmallenberg, Germany
Phone +49 2972 302270

Fraunhofer Institute for Toxicology and Experimental Medicine ITEM
Nikolai-Fuchs-Str. 1
Main entrance: Stadtfelddamm
30625 Hannover, Germany
Phone +49 511 5350-8100
info@item.fraunhofer.de

Fraunhofer Institute for Process Engineering and Packaging IVV
Giggenhauser Strasse 35
85354 Freising, Germany
Phone +49 8161 491-100
info@ivv.fraunhofer.de

Fraunhofer Institute for Cell Therapy and Immunology IZI
Perlickstrasse 1
04103 Leipzig, Germany
Phone +49 341 35536-1000
info@izi.fraunhofer.de

Bioanalytics and Bioprocesses branch
in Potsdam-Golm
Am Mühlenberg 13
14476 Potsdam-Golm, Germany
Phone +49 331 58187-102

Fraunhofer Research Institution for Marine Biotechnology and Cell Technology EMB
Mönkhofer Weg 239a
23562 Lübeck, Germany
Phone +49 451 384448-10
info@emb.fraunhofer.de

For further information about the individual institutes, please refer to the Group's homepage at **www.lifesciences.fraunhofer.de**

SWISS BIOTECH™
National Thematic Network

SWISS BIOTECH DAY 2018

The leading Life Sciences Conference in Switzerland and Annual General Assembly of the Swiss Biotech Association

Picture: ©Basel Tourismus

Picture: © Rynacher/ https://commons.wikimedia.org/wiki/File:Basilisk_Wettsteinbrücke.JPG (CC BY-SA 3.0); GNU Free Documentation License

Join the Swiss Biotech Day, the leading biotechnology conference in Switzerland. The event is not just the place to be for members of the Swiss Biotech Association, who traditionally meet there for the association's Annual General Assembly. As always, the event brings together entrepreneurs, investors, researchers, analysts, political decision makers and industry stakeholders.

Don't miss the keynote by the assigned CEO of Novartis, Vasant Narasimhan, and meet around 600 experts from across Europe.

All information on programme, exhibitors, sponsoring and registration can be found at www.swissbiotechday.ch.

3 MAY 2018
Basel Congress Center

Sponsors:

KPMG · SIX Swiss Exchange · IQVIA · PIS 20 Years · BIOTEZ · Microsynth · MORGAN SINDALL PROFESSIONAL SERVICES · SOCOREX SWISS · biopôle · JAG Process Solutions · M+W GROUP · mlm medical labs · DrM Single-Use Filtration and Mixing · Kneat · INNOMEDICA · BIOMAPAS · CES Freezing Technology · HASELMEIER

Supporting Partners:

Departement für Wirtschaft, Soziales und Umwelt des Kantons Basel-Stadt
Amt für Wirtschaft und Arbeit

LSZ YSN · BASEL AREA. SWISS · European Biotechnology Network

Swiss Industry Science Fund (SISF)
BASF · syngenta · NOVARTIS · Roche

Media Partners:

transkript · European Biotechnology Life Sciences and Industry Magazine · LABORWELT

Organised by:

Swiss Biotech Association · BIOCOM AG

Opening & Plenary Session | Room Spectrum

Time	Title / Speaker	Contact
Opening Session		
8:45	Introduction	
8:50	Welcome address	
	 **Prof. Dr. Frank Emmrich** Director Fraunhofer Institute for Cell Therapy and Immunology IZI, DE	frank.emmrich@izi.fraunhofer.de www.izi.fraunhofer.de
9:00	Setting the scene	
	 **Dr. Marc Gitzinger (session chair)** CEO and co-founder BioVersys AG, CH	marc.gitzinger@bioversys.com www.bioversys.com
Plenary Session		
Keynotes		
9:10	Addressing drug-resistant infections: a global and collaborative endeavour	
	 **Jean-Pierre Paccaud, PhD** Director of Business Development and Corporate Strategy Global Antibiotic R&D Partnership (GARDP), CH	jppaccaud@dndi.org www.gardp.org
9:30	Feeding the AMR pipeline through innovation – challenges and solutions for European SMEs	
	 **Mark Jones, PhD** Head of Project Management and Head of PreClinical Development Basilea Pharmaceutica Ltd., CH	mark.jones@basilea.com www.basilea.com
9:50	Replenishing and enabling the pipeline for anti-infective resistance	
	 **Aleks Engel, PhD** Partner Novo Seeds and Director Repair Impact Fund Novo Holdings Repair Impact Fund, DK	aeee@novo.dk www.novonordisk.com
	 **Prof. George E Griffin, PhD** Chair of fund SAB Novo Holdings Repair Impact Fund & Emeritus Professor of Infectious Diseases and Medicine St George's, University of London, UK	ggriffin@sgul.ac.uk www.novonordisk.com
10:10	The challenge of bringing successful AMR diagnostics to the clinic	
	 **Jorge Villacian, MD** CMO Janssen Diagnostics, Janssen Pharmaceutical R&D, Johnson & Johnson, BE	jvillaci@its.jnj.com www.janssen.com
10:30	Coffee break with posters & exhibition	

SCIENTIST & LAWYER

For more than 80 years we are where you are and we deeply understand your business. From all perspectives and in all aspects. In all technical and legal fields of intellectual property. With an interdisciplinary team of patent and legal professionals.

www.boehmert.de

BOEHMERT & BOEHMERT

BALANCING GENERIC AND INNOVATIVE MEDICAL USES – A WAY OUT OF AMR?

Dr. Ute Kilger, Partner, BOEHMERT & BOEHMERT, Berlin, Germany

Antimicrobial resistance (AMR) is set to become a global threat but a new look at old drugs may help in the fight against it. In fact, recent research suggest that repurposing drugs could be the key to effectively target the rising antibiotic crisis. In November 2017, for instance, it has been discovered that a drug marketed as glatiramer acetate or Copaxone, which has been used in the treatment of multiple sclerosis for 20 years, obviously kills antibiotic-resistant bacteria. The question, however, is whether there is also a business model behind repurposing old drugs to fight AMR, i.e. whether the innovator has any chance of obtaining a return on such an investment.

Innovative pharmaceutical companies develop new drugs and invest hundreds of millions of Euros in bringing them onto the market. Return on investment is secured by market exclusivity limited to a specific period of time provided by patents and data exclusivity (no generic company can rely on the originator's clinical data for market approval). The originator therefore has time to obtain a return on investment for a limited period before the generics enter the market. This "ecosystem" works quite well for any new compound.

It does not work that well, however, for the development of known and/or marketed substances in a new medical indication – as it would be the case with repurposing old drugs in the AMR field. Substantial problems remain to be solved – problems that are not limited to the antibiotics arena. The development of a new medical use for a known marketed substance also requires substantial investment in development and clinical trials. Such an investment may be USD 0.5 billion and 5 years less than that needed for a new compound, but pharmaceutical or biotech companies cannot justify this level of expense and risk if the generic companies are also able to sell the "old" drug for the new use, leaving the originator with no chance of getting a return on its investment. This holds especially true in the field of antibiotics where the expectation is that antibiotics should be cheap.

Not solving this problem would be detrimental to mankind. It is often the case that a medically active compound is useful in several diseases. And it may well be that the second or third medical use discovered is particularly valuable, as in the case of AMR. Thus, there is a need for a regulatory and legal system that facilitates both cases – incentivizing the development of a new use and allowing the generic company to sell the drug for the patent-free old use. Substitution rules and tenders imposed by health insurers mean that pharmacists would have to dispense the cheapest (generic) medicine having the same compound without even knowing which indication it had been prescribed for, since doctors would prescribe the compound without specifying the indication. This would inevitably lead to the generic being dispensed in a manner infringing the patent, thus destroying the market and any incentives for the originator.

Denmark amended the legislation when the Danish courts ruled on such a case, involving Pregabalin, to enable a split market where both ends can be accomplished: as a generic drug for the old use and as an originator drug for the new use. Other courts in Europe, e.g. in Germany, addressed this issue by requiring that the health insurer's tender must be limited to the patent-free indication, but this proved insufficient as pharmacists still dispensed the generic drug for all uses.

This February, Georgetown University (D.C.) and Sir Robin Jacob from the UCL, London, invited think-tanks to a conference in Washington D.C. where various experts and stakeholders discussed how to achieve both ends, while considering options such as split markets. One thing, however, is very clear: this requires more than aligning the generic and innovative companies, which would be doable, it also means aligning lawmakers, politicians, and health insurers. It is neither an easy nor a popular task to explain why the same medicine should be low in price in the generic, old indication but high in price in the new indication. It is easier to say: Hauptsache günstig (the main thing is it's cheap).

The same case, the Pregabalin case, was heard very recently before the UK Supreme Court and observers stated that unfortunately the discussion focused very much on the potential deterrent effect on generics for patent-free uses and much less on the deterrent effect on innovators seeking to find new uses. If this held true, and originators stopped finding and developing new uses, it would be bad news for all of us. It is therefore to be hoped that reason will prevail and legislators will be willing to find ways to incentivize the development of new uses despite generics still being dispensed for their old use.

Session 1 | Room Spectrum

Market access in the era of AMR – from idea to product

supported by

BOEHMERT & BOEHMERT

Time	Title / Speaker	Contact
11:00	**The patent perspective: How to protect IP in a field of multiple public, private and public/private collaborations?**	
	 **Dr. Markus Engelhard (Session Chair)** European Patent and Trademark Attorney, Pharma/Life Sciences BOEHMERT & BOEHMERT, DE	engelhard@boehmert.de www.boehmert.de
11:15	**A new breakthrough class of Gram-negative antibiotics**	
	 **Dr. Glenn Dale** Head of Antibiotic Research and Early Development Polyphor Ltd., CH	glenn.dale@polyphor.com www.polyphor.com
11:30	**Panel discussion: "Efficacy evaluation for novel antimicrobial approaches: current challenges and new routes"**	
	 **Dr. Nicolas Tesse (panel moderator)** Directeur Scientifique SEPTEOS SAS, FR nicolas.tesse@neteos-groupe.com	
	 **Guennaëlle Dieppois, PhD** Senior Scientist Antimicrobial Development Debiopharm Int. SA, CH guennaelle.dieppois@debiopharm.com	
	 **Dr. Glenn Dale** Head of Antibiotic Research and Early Development Polyphor Ltd., CH glenn.dale@polyphor.com	
	 **Prof. Dr. Johan W. Mouton** Professor for Pharmacokinetics and Pharmacodynamics Erasmus University Rotterdam, NL jwmouton@gmail.com	
12:00	**Accelerating diagnostics use to prevent AMR on a global level**	
	 **Dr. Catharina Boehme** CEO FIND Diagnostics, CH	Catharina.Boehme@finddx.org www.finddx.org
12:15	**Sustainable economic models to revitalise antibiotic development – lessons learned from DRIVE-AB**	
	 **Dr. Christine Årdal** Senior Advisor Norwegian Institute of Public Health, NO	chaa@fhi.no www.fhi.no
12:30	**Panel discussion: How to bring AMR innovation to the market?**	
	 **Dr. Christine Årdal (panel moderator)** Senior Advisor Norwegian Institute of Public Health, NO chaa@fhi.no	
	 **Prof. Anders Karlén, PhD** Leader of the managing entity of ENABLE Uppsala University, SE anders.karlen@ilk.uu.se	
	 **Ghada Zoubiane, PhD** Science Lead, Drug-Resistant Infections Wellcome Trust, UK G.Zoubiane@wellcome.ac.uk	
12:55	**Lunch break with posters & exhibition**	

supported by

FLANDERS INVESTMENT & TRADE

Session 2 | Room Forum

From basic research to market –
recent academic anti-infective and diagnostics innovations

Time	Title / Speaker	Contact
11:00	**Is AMR becoming the greatest challenge in global public health?**	
	 **Dr. Jan Wauters** Science and Technology Counselor Life Sciences and Nanotechnologies Flanders Investment & Trade, Government of Flanders, US	jan.wauters@fitagency.com www.fitagency.com
11:10	**The value of academic research in AMR innovations**	
	 **Prof. Herman Goossens, MD** Head of LMM, Vaccine & Infectious Disease Institute University of Antwerp, BE	Herman.Goossens@uza.be www.uantwerpen.be/en
11:25	**Tackling AMR via innovative natural products**	
	 **Prof. Dr. Rolf Müller** Managing Director, Helmholtz Institute for Pharmaceutical Research (HIPS) & Coordinator „Novel Antibiotics“, German Center for Infection Research (DZIF), DE	Rolf.Mueller@helmholtz-hzi.de www.helmholtz-hzi.de www.dzif.de/forschung/neue-antibiotika
11:40	**First clinical results of cold plasma treated chronic infected wounds**	
	 **Dr. Kai Masur** Principal Investigator Leibniz Institute for Plasma Science and Technology, DE	kai.masur@inp-greifswald.de www.leibniz-inp.de
11:55	**Identification of novel antimicrobials using cell-free systems**	
	 **Dr. Stefan Kubick** Head of Department of Cell-free and Cell-based Bioproduction Fraunhofer Institute for Cell Therapy and Immunology IZI, Branch Bioanalytics and Bioprocesses, Potsdam-Golm (IZI-BB), DE	Stefan.Kubick@izi-bb.fraunhofer.de www.izi.fraunhofer.de
12:10	**Antibiotics research at the Institut Pasteur in Paris and in the Institut Pasteur International Network**	
	 **Dr. Philippe Glaser** Head of the Ecology and Evolution of Antibiotic Resistance Unit Department of Microbiology Institut Pasteur, FR	philippe.glaser@pasteur.fr https://research.pasteur.fr
12:25	**Diagnostic tools to distinguish between bacterial and viral infections to reduce antibiotic abuse**	
	 **Prof. Per Venge, MD PhD** Professor in Clinical Chemistry Department of Medical Sciences Uppsala University, SE	per.venge@medsci.uu.se www.medscie.uu.se
12:40	**Rapid diagnostics – from barriers to solutions for AMR**	
	 **Dr. Till Bachmann** Deputy Head of Division of Infection and Pathway Medicine Edinburgh Medical School, Biomedical Sciences University of Edinburgh, UK	till.bachmann@ed.ac.uk www.ed.ac.uk/pathway-medicine
12:55	**Lunch break with posters & exhibition**	

Flanders: The Life Sciences Nucleus of Western Europe

Flanders, a region comprising the northern half of Belgium, might be small in surface area, but it's home to one of the most vibrant life sciences ecosystems in the world. And for good reason; Flanders' strategic location, vivid network of global life sciences players, excellent supportive incentives and talented workforce make it 'the place to be' to thrive in any life sciences subsector.

An Ecosystem that Brings Life Sciences to Life

The European knowledge economy is driven in a large part by Flanders, which combines a range of government supported and private R&D platforms, scientific institutes and strategic research centres active in a range of science and technology domains.

A high level of academic-industrial collaboration in Flanders results in a dense network of human health industry players, resources and driving forces that rely on each other and build upon shared innovations. Even more, due to its knowledge economy and atmosphere of open innovation, small-scale start-ups in Flanders are able to work alongside – and compete with – global industry players.

Key Strategic Research Centres

As a strategic research centre for nanotechnology, imec is a renowned synonym for 'cutting-edge'. It plays a crucial role in the design of electronics for pharma and healthcare, focusing on technologies that steer easier diagnosis and more comprehensive treatment like labs-on-chips, neuroprobes, health wearables and more. As a pioneer in digital technologies, the centre possesses unparalleled expertise in applications revolving around health and care, including robotics, medical device optimisation, prostheses and care services planning.

Digital Domination: imec Strengthens its Pole Position

A new five-year agreement brings an extra EUR 29 million to imec in 2017 with the goal of keeping Flanders at the head of the medical biotech pack. Operating one of Europe's most productive start-up incubators and giving rise to 78 spin-offs in the last handful of years, imec also applies for approximately 120 science and tech patents per year.

With a dual-pronged approach that combines basic research and translational initiatives, VIB, Flanders' institute for biotechnology, is a vast source of knowledge, expertise and infrastructure relevant to pharmaceutical, agricultural and industrial applications. Its scientists are globally recognised frontrunners in their fields. VIB's 10 core facilities support research and innovation by providing highly-advanced 'omics' technologies and research capacities to external organisations and private companies.

The World's Most Fertile Soil for Bio Innovation

Founded in 1996, VIB has taken the world by storm, attracting the brightest minds in biosciences to conduct basic research with the ultimate goal of using their insights to benefit society. VIB employs approximately 1470 scientists from more than 60 countries, who have been responsible for major breakthroughs that have rocked the fields of cancer research, immunology and inflammation, neurobiology and molecular neurology, microbiology, medical biotechnology, structural biology and plant systems biology. Pioneering spin-offs, including ADX Neuroscience, Actobiotics, ThromboGenics and Formac Pharmaceuticals, have been launched by this international powerhouse of biotechnology knowledge.

Pharma-medical Collaborations in the Spotlight

World-changing ideas can't take flight in a vacuum. Interaction is always a key ingredient. As many as 77 pharma companies with locations in Flanders and Belgium as a whole channelled EUR 2.89 billion into R&D in 2016,[1] mainly through collaborations with healthcare organisations and professionals.

Home to Every Incentive for Success

Achieving sustainable growth for your pharma, biotech or biomed business is smooth sailing in Flanders thanks to the region's worldwide reputation for bright ideas – the fourth highestscoring nation in the world for innovation[2] and the first in Europe for cooperation between scientific institutions and SMEs.[3]

Flanders' R&D-friendly tax system 101

Innovation income deduction
up to **85%** of net innovation incomes exempt from corporate taxation

R&D payroll tax incentive
recover up to **80%** of the withholding tax on professional income for researchers

R&D investment deduction
13.5% of the investment value (at once)
20.5% of the annual depreciation (staggered)

Pharma in Flanders

#2 in Europe for number of clinical trials per capita

Fastest clinical approval in EU (15 days)

5% of global pharma output is developed here.

Did you know that researchers from Flanders...

...were the first to unravel the DNA sequence of a gene?

...developed pioneering pharmaceuticals ...were the first to use stem cells in bone marrow transplants?

...created a lab-on-a-chip for early breast cancer discovery?

Belgium/ Flanders ranks #1 for industrial-academic linkages[4]



Significant Tax Savings on Novel Ideas

Developing the next disruptive biotechnology or ground-breaking medicine? The region offers incentives that target research-heavy sectors such as pharma and biotech. The innovation income deduction renders up to 85% of a firm's net earnings from innovation tax exempt, allowing companies to reinvest the funds to fuel ongoing development.

Other Generous Incentives for R&D Initiatives

The investment deduction for R&D is worth 13.5% of the acquisition value or qualifying asset, or 20.5% of the depreciated amount of the investment. R&D companies are also exempt from paying 80% of the personal income withholding tax of researchers in specific scientific fields.

Got Innovation? Get in Touch with VLAIO

Flanders Innovation & Entrepreneurship (VLAIO), a governmental organisation responsible for stimulating growth, innovation and entrepreneurship, is the ideal funding partner for companies in any domain developing new products and services. Depending on the type of R&D activity and company, VLAIO offers a number of support programmes and grants that can fund up to 60% of your innovation project.

Where International Life Sciences Professionals Thrive

A broad range of fiscal advantages are offered by the Government of Flanders to expatriate employers, managers and executive personnel working in the region on a temporary basis. These include tax-free expat allowances covering living and housing costs, and unlimited tax reimbursement of moving expenses, schooling costs and more.

As previously mentioned, targeted R&D staff employment advantages can exempt companies from paying up to 80% of the payroll withholding tax of scientists and skilled technicians such as PhDs, engineers and personnel with master's degrees.

In addition to the financial and tax incentives, Flanders is a great place to live. It has an enterprising, lively atmosphere that places emphasis on art, culture and history as well as new technologies and modern pursuits. Its advanced healthcare system is comprehensive and easy to use, and its high standard of living and relatively low costs are significant draws.

Connect with Flanders Investment & Trade

Flanders Investment & Trade (FIT) is your source of expertise regarding every aspect of doing business in Flanders. This governmental organisation provides comprehensive support for companies seeking to invest in and source from Flanders via its 90 offices worldwide. In addition to its broad network of stakeholders, working with FIT brings companies the benefits of tailored data, business-relevant insights and expert advice tailored to their unique situation.

In partnership with VIB, VLAIO and FlandersBio, Flanders Investment & Trade offers the services of a skilled life sciences welcome team dedicated to providing support and guidance to foreign life sciences and biotechnology investors in Flanders.

Flanders Investment & Trade - Berlin

berlin@fitagency.com
www.investinflanders.com
@Flandern_DE @InvestFlanders

References

1. beTransparent.be
2. ZEW Center for European Economic Research, Innovation Indicator 2014
3. Innovations Indikator 2015; Bloomberg Innovation Index 2017
4. European Commission, European Innovation Scoreboard, 2017

Session 3 | Room Spectrum

Technology highlights and challenges – novel antimicrobials

supported by BEAM Alliance

Time	Title / Speaker	Contact
13:50	**Introduction: The value of SMEs in AMR innovations**	
	 **Marie Petit (session chair)** Coordinator BEAM Alliance, FR	marie.petit@beam-alliance.eu https://beam-alliance.eu
14:00	**Priority setting for R&D of new antibiotics – the WHO perspective**	
	 **Sarah Paulin, PhD** Technical Officer Innovation, Access and Use Unit Department of Essential Medicines and Health Products World Health Organization, CH	paulins@who.int www.who.int/medicines/en
14:15	**Fostering investment in AMR innovation – the UNCTAD World Investment Forum 2018**	
	 **Christoph Spennemann** Legal Officer and Officer-in-Charge Intellectual Property Unit, Division on Investment and Enterprise UNCTAD, CH	Christoph.Spennemann@unctad.org http://unctad.org/ddip
14:30	**The need for coordination: the global AMR R&D hub**	
	 **Andrea Spelberg** Head of Division 616 – Head of Research for Global Health Unit Federal Ministry of Education and Research, DE	Andrea.Spelberg@bmbf.bund.de www.bmbf.de
14:40	**Insights into the development of anti-infective therapies in AMR dedicated SMEs in Europe**	
	The development of a synthetic branched peptide for fighting multi-resistant Gram-negative bacteria	
	 **Prof. Alessandro Pini, PhD** CEO SetLance srl, IT	pinia@unisi.it www.setlance.com
	Six birds by two stones – the development of ASN100, a monoclonal antibody product candidate targeting Staphylococcus aureus	
	 **Zoltán Magyarics, MD, PhD** Medical Director Arsanis Inc., US/AT	zoltan.magyarics@arsanis.com www.arsanis.com
	Artilysin® – an intelligent platform technology to combat MDR pathogens	
	 **Martin Grießl** Deputy Director R&D Head of Protein Design Lysando AG, DE	martin.griessl@lisando.com www.lisando.com
15:10	**Leveraging technology to spur antibiotic discovery**	
	 **Dr. Mariana Vaschetto** Head of European Operations Collaborative Drug Discovery Inc., UK	mariana@collaborativedrug.com www.collaborativedrug.com
15:25	**Coffee break with posters & exhibition**	

Session 4 | Room Forum

Technology highlights and challenges – diagnostics

Time	Title / Speaker	Contact
13:50	**Platforms, biomarkers, data: an industry perspective on molecular microbiology**	
	 **Dr. Achim Plum** CBO Curetis N.V., DE	achim.plum@curetis.com www.curetis.com
14:05	**Bringing photonics to the clinic: concept for an user-open center for photonics in infection research**	
	 **Prof. Dr. Jürgen Popp** Managing Board, InfectoGnostics Research Campus Jena & Scientific Director, Leibniz Institute of Photonic Technology e.V., DE	juergen.popp@leibniz-ipht.de www.leibniz-ipht.de
14:20	**Rapid tests to detect antibiotic resistance**	
	 **Bruce Savage** CEO GFC Diagnostics, UK	brucesavage@gfcdiagnostics.com www.gfcdiagnostics.com
14:35	**Development of diagnostics for antimicrobial resistance – a company perspective**	
	 **Dr. Ralf Ehricht** Senior Principal Scientist Feasibility Studies Abbott (former Alere Technologies GmbH), DE	ralf.ehricht@alere.com www.alere-technologies.com
14:50	**Pulse Controlled Amplification: A platform technology for ultrafast AMR diagnostics and beyond**	
	 **Dr. Lars Ullerich** Managing Director – Business Development GNA Biosolutions GmbH, DE	ullerich@gna-bio.com www.gna-bio.com
15:05	**Concept ≠ Technology ≠ Product. What it takes to create an actionable Dx in the fight against AMR**	
	 **Kfir Oved, PhD, MD** CTO & Co-Founder MeMed Diagnostics Ltd, IL	kfiroved@me-med.com www.me-med.com
15:25	**Coffee break with posters & exhibition**	

The UK: your partner for developing and commercialising solutions for antimicrobial resistance

From the discovery of Penicillin to the development of rapid point-of-care tests and genomic screening, the UK has always led the world in trying to better understand, detect, diagnose, treat, and control infectious diseases and the growing challenge of antimicrobial resistance (AMR).

We offer cutting-edge research and talent, established platforms for innovation and clinical trials, support for technology development and informatics capabilities, world-renowned public health and regulatory expertise and global standards, a culture of collaboration with access to partners, and a launch-pad to global markets for prevention, diagnosis, treatment and disease management.

700,000

people die each year from drug resistant diseases

Why select the UK for developing antimicrobial resistance solutions?

- A world class research base, cluster, and talent pool.
- **Global leadership:** The Review on Antimicrobial Resistance (AMR), commissioned in July 2014 by the UK Prime Minister made 10 recommendations to reduce over-prescribing, increase the number of new antibiotics that come to market, and build a global coalition for action on AMR.
- **Financial commitment to research:** The UK Government will build on its investment in AMR R&D in the coming years. It recently funded over £64m of AMR-related projects through the National Institute for Health Research and Research Council programmes. Other schemes encouraging international research collaboration include the £1bn Ross Fund to tackle malaria and infectious diseases; the £1.5bn Global Challenges Research Fund, the Fleming and Newton Funds, and the Global Antimicrobial Resistance Innovation Fund.
- **A clinical trial and testbed platform through the National Health Service (NHS)**: The NHS is the world's largest integrated healthcare system, treating more than 60 million people, with over £1bn annual investment in a national platform for clinical research and study support service for sponsors and CROs.
- **A strong industry cluster** covering discovery and development of vaccines, therapeutics, diagnostics, informatics and One Health approaches (encompassing human and animal health), and a strong Clinical Research Organisation base.

National infrastructure for treatment, diagnostic and AMR systems research and development

- **Genomics England**, established in 2013, is currently the largest national sequencing project of its kind in the world. Public Health England has been asked to lead the infectious disease part of the 100,000 Genome Project, focussing on the application of whole genome sequencing in diseases such as tuberculosis.
- The UK is investing up to £66m in capital funding to build and establish a good manufacturing practice (GMP)-capable **UK National Vaccines Development and Manufacturing Centre.**
- **Wellcome Trust**, one of the world's leading funders of biomedical R&D, supports global efforts in antimicrobial resistance through co-funding of the CARB-X scheme.
- **Two National Institute for Health Research (NIHR) Health Protection research Units** are focused on Healthcare Associated Infections (HCAIs) and AMR, leading on research to support the development of effective approaches to combat AMR. Also part of the NIHR, **four Biomedical Research Centres** (in Cambridge, Oxford and two in London linked to Imperial and University College London Hospitals) conduct translational research to transform scientific breakthroughs into life-saving treatments for patients.

Reducing the risks and creating an efficient route to product development

- More than 150 companies working on infection management and treatment have benefited from funding of over £58m over the last 10 years through **Innovate UK**, the UK's national innovation agency, with a focus on commercial translation.
- The **Medicines Discovery Catapult** based at Alderley Park will focus on medicines; diagnostics; biomarkers; and early-stage clinical trial support. The Catapult will serve as a community one-stop shop for all drug-based approaches.
- **NIHR In vitro Diagnostics Co-operatives** in London, Leeds Newcastle and Oxford support companies developing the evidence and evaluating diagnostics to support commercialisation.
- The **MHRA Innovation Office,** offering a single point of access for all innovative medicines and medical devices, is a key resource for all developers in the personalised medicine area.
- The **Early Access to Medicines Scheme** makes promising new unlicensed medicines available to UK patients at an earlier stage, especially in areas of high unmet clinical need.

The UK's Department for International Trade (DIT) is the specialist Government department that

· helps UK-based companies access overseas markets, providing confidential advice and support necessary to assist you in achieving your export goals.

· helps overseas companies bring their high-level investment to the UK, providing professional, personalised and practical assistance and advice.

These services are offered through DIT's extensive network of sector and market specialists both in the UK and in British embassies and diplomatic offices around the world.

For further information please contact:

Rachel Postert
Senior Business Development Manager
Tel: +49 (0)211 9448 155
Email: Rachel.postert@mobile.trade.gov.uk

or

Laurie Williams
Business Development Manager
Tel: +49 (0)211 9448 276
Email: Laurie.Williams@mobile.trade.gov.uk

Please follow us on Twitter @tradegovukDEU
www.great.gov.uk

100 million deaths

Number of deaths annually by 2050 if AMR isn't addressed

$100 trillion

Estimated lost economic output due to AMR

INNOVATION IS GREAT
BRITAIN & NORTHERN IRELAND

Start-up pitch

The development of new therapeutics and diagnostics to combat antimicrobial resistance is more relevant today than ever before. Although the business environment is tough, start-ups in Europe advance new technologies in the field. The session will highlight seven new ventures and will discuss the topic from an investor's perspective.

Contact:
Ajay Mistry, PhD
Founder/CEO
Ajay.Mistry@oppilotech.com

Company: **Oppilotech Ltd.**
Founded: **2015** Employees: **3**
Investors: **Angels (small investment round in 2017)**
Market: **Detailed metabolic modeling, systems biology, gram-negative outer membrane model, LPS, phospholipids, potentiators**

London Bioscience Innovation Centre
2 Royal College Street,
London NW1 0NH, UK
Tel: +44 788 181 1739
Web: www.oppilotech.com

Contact:
Dr. Juan José Infante Viñolo
CEO
juanjo.infante@vaxdyn.com

Company: **Vaxdyn S.L**
Founded: **2011** Employees: **6**
Location: **Seville and Madrid**
Investors: **Insynchrony ventures (Insymbiosis Group), Dr. Francisco León, private investment group from Madrid, founding partners, Dr. Juan J. Infante**
Market: **Immunotherapy, bacterial infections, prevention, safe cellular vaccines, antimicrobial resistance, Acinetobacter baumannii**

Campus Hospital Virgen del Rocío. Av. Manuel Siurot s/n
41013 Seville, ES
Tel.: +34 606660701 | Web: www.vaxdyn.com

Contact:
Dr. Andreas A. Bastian
CEO
a.a.bastian@agilebiotics.com

Company: **AGILeBiotics B.V.**
Founded: **2017** Employees: **3**
Location: **Innolab Chemie Groningen**
Investors: **RUG Houdstermaatschappij B.V., Hanzepoort B.V., Stichting Ir. G. J. Smid Fonds B.V.**
Market: **Reviving antibiotics, selective modification, bacterial resistance, MDR Gram-negative infections, superbug infections**

De Mudden 14
9747 AW Groningen, NL
Web: https://agilebiotics.com

Company: **SpinDiag GmbH**
Founded: **2016** Employees: **8**
Location: **Freiburg**
Investors: **Undisclosed**
Market: **Antibiotic resistance, diagnostics, point-of-care**

Contact:
Dr. Daniel Mark
CEO
Daniel.Mark@spindiag.de

Engesserstr. 4
79108 Freiburg, DE
Tel.: +46 761 203 73246
Web: www.spindiag.de

Company: **PhagoMed Biopharma GmbH**
Founded: **2017**
Employees: **hiring to complete founding team**
Location: **Vienna and Berlin**
Investors: **Angels Investors and Family Offices**
Market: **Pre-clinical biotech venture focused on human phage therapy (lead indication: periprosthetic joint infections)**

Contact:
Alexander Belcredi
CEO
alexander.belcredi@phagomed.com

Goldeggasse 6, Top 5–6,
1040 Wien, AT
Tel.: +43 676 38 11 082
Web: www.phagomed.com

Company: **Resistell**
Founded: **in foundation** Employees: **8 (founding team)**
Location: **Basel & Lausanne**
Investors: **–**
Market: **World's fastest antibiotic resistance test; Saving lives by finding the right antibiotic on time**

Contact:
Dr. Danuta Cichocka
CEO
danuta.cichocka@resistell.com

Basel Inkubator
Hochbergerstr. 60c
4057 Basel, CH
Tel.: +41 79 899 91 88
Web: www.resistell.com

Company: **FASTinov AS**
Founded: **2013** Employees: **5**
Location: **Porto, Portugal**
Investors: **Founders – Acácio Rodrigues, Cidália Pina-Vaz, Sofia Oliveira; Corporate Investors: Armilar Ventures P. (I-START FUND); Busy Angels FCR (FCR Leading Ventures)**
Market: **AMR, antimicrobial susceptibility testing, AST/ID, flow cytometry, antimicrobial resistance, infectious diseases, MIC**

Contact:
António Ornelas-Soares
Executive Board Member
antoniosoares@fastinov.com

Rua Alfredo Allen n 455/461 sala 17, 4200-135 Porto, PT
Tel.: +35 1966321139
Web: www.fastinov.com

Resistell

GOLD STANDARD

RESISTELL

The world's fastest antibiotic resistance test

WITH RESISTELL YOU CAN MOVE MUCH FASTER

We not only save lives by providing the right drug on time, but also prevent spreading of antibiotic resistance.

- Based on detecting physical movement of living bacteria
- AST results in minutes not days
- Precise MIC / MBC
- Clinical impact: Effective treatment starts on the same day!

Website
resistell.com

Investor relations
danuta.cichocka@resistell.com
+41 79 899 91 88

Address
Resistell
Hochbergerstr. 60c
CH 4057 Basel

Resistell: A revolutionary new tool in the fight against antibiotic resistance

Antibiotic resistance is one of the most urgent issues in global medicine today. It's estimated that antibiotic resistance could kill 10 million people a year by 2050 if new and faster methods aren't found to identify effective drugs. Enter Resistell, the world's fastest antibiotic resistance test. It not only saves lives by identifying the right drug in time, but it also prevents the spread of antibiotic resistance.

Resistell is pioneering a new technology that seeks to revolutionise the detection of antibiotic resistance by drastically reducing the time it takes to identify the most effective drug from days to minutes.

While conventional antibiograms require isolating the bacteria and growing a culture, Resistell uses a sensor placed inside a microfluidic chamber that detects movement of bacteria. Antibiotics are introduced into the chamber to test resistance based on nanomotion. The lack of bacterial movement instantly indicates drug susceptibility. This happens in a matter of minutes rather than days and enables doctors to choose the most effective drug right from the start and, ultimately, saving lives.

The clinical and financial impact of Resistell is huge. Quicker test results mean reduced mortality rates. The ability to identify the right drug on time leads to less severe medical effects and conditions. Fast and targeted treatment significantly reduces the costs for the entire healthcare system.

To date, Resistell has shown almost

100% accuracy

across samples.

For more information, and investors relations contact Dr Danuta Cichocka, CEO of Resistell:

danuta.cichocka@resistell.com
+41 79 899 91 88

Hochbergerstr. 60c
CH 4057 Basel

resistell.com

Jury start-up pitch & investors talk

Time	Title / Speaker	Contact
15:50	 **Henri-François Boedt** Senior Loan Officer Growth Capital and Innovation Finance European Investment Bank, LU	h.boedt@eib.org www.eib.org/products/blending/innovfin/products/infectious-diseases.htm
	 **Emmanuelle Coutanceau, PhD** Partner Novo Holdings Repair Impact Fund, DK	ecou@novo.dk www.novo.dk
	 **Aleks Engel, PhD** Partner Novo Seeds and Director Repair Impact Fund Novo Holdings Repair Impact Fund, DK	aeee@novo.dk www.novonordisk.com
	 **Dr. Peter Jackson** Executive Director AMR Centre Ltd, UK	peter.jackson@amrcentre.com www.amrcentre.com
	 **Prof. Kevin Outterson** Executive Director CARB-X, US	mko@bu.edu www.carb-x.org
	 **Dr. med. Beat Steffen** Principal Novartis Venture Fund, CH	beat.steffen@nvfund.com www.nvfund.com

Interactive Marketplace

ND4BB ENABLE

AMR CENTRE

wellcome

European Investment Bank The EU bank

nadp netherlands antibiotic development platform

CARB-X

GARDP Global Antibiotic Research & Development Partnership

repair impact fund novo holdings

NF FUNDED BY NOVARTIS

Notes

BIOCOM AG

In this stores
biocom.de/app

CDD VAULT®

Complexity Simplified™



Smart Drug Discovery Software Saves Time

CDD Vault is a complete platform for drug discovery informatics, hosted through an intuitive web interface. It helps your project team manage, analyse, and present chemical structures and biological assay data

Activity & Registration
Store and organize your data

Store, Search, Analyze, & Report

CDD Vault is a modern web application for your chemical registration, assay data management and SAR analysis. It lets you organize drug discovery data and collaborate across project teams. It is simple to use and extremely secure.

Visualization
Plot datasets and mine them

Interact, Calculate, Compare & Publish

CDD Vault is a dynamic analysis tool for drug discovery data. It lets you plot and analyze large data sets to find interesting patterns, activity hotspots and outliers. With publication quality graphics, it is easy to illustrate and share results across project teams.

Inventory
Keep track of compounds

Debit, Track & Locate

CDD Vault is an Integrated inventory system for your compounds and reagents. Stay informed of the current status of your inventory whether in-house or shared externally.

ELN
Document all your research

Capture, Search, Protect & Work Together

CDD Vault is the ultimate electronic lab notebook, integrated directly with the chemical and biological assay data repositories and our full analysis and visualization environment. Designed for project teams, you can archive and search all of your experiments with ease and collaborate securely.

Start Your Free Trial Today
www.collaborativedrug.com/cdd-vault

BIOCOM Event

Poster Exhibition

Fraunhofer-Gesellschaft

DNA microarrays for the highly parallel, fast and sensitive molecular discrimination of pathogens and associated resistances
Susanne Bailer
susanne.bailer@igb.fraunhofer.de

Novel approaches to mimic persistent, biofilm-associated Pseudomonas aeruginosa respiratory infection in vitro and ex vivo
Sabine Wronski
sabine.wronski@item.fraunhofer.de

Rapid on-site activity test of ß-lactamase-producing bacteria
Cornelia Hettrich
cornelia.hettrich@izi-bb.fraunhofer.de

Use of antimicrobial peptides for the reduction of multi-resistant pathogenic bacteria and prevention of biofilm formation
Markus von Nickisch-Rosenegk
markus.nickisch@izi-bb.fraunhofer.de

Vaccine testing and drug validation using infection mouse models
Thomas Grunwald
thomas.grunwald@izi.fraunhofer.de

German Center for Infection Research (DZIF)

Fragment-based carbapenemase inhibitors
Hannelore Meyer, Hannelore.Meyer@tum.de

Pre-clinical development of the antibiotic Corallopyronin A
Achim Hoerauf, achim.hoerauf@ukbonn.de

Amidochelocardin, a bioengineered atypical tetracycline with broad-spectrum antibiotic activity
Marcus Miethke, marcus.miethke@helmholtz-hzi.de

Cystobactamids – molecules derived from natural products active against multi-resistant Gram-positive and Gram-negative pathogens: a journey from discovery to early pre-clinical development
Katharina Rox, katharina.rox@helmholtz-hzi.de

Lead generation and optimization of PqsR antagonists for the treatment of chronic pseudomonas aeruginosa infections
Martin Empting, martin.empting@helmholtz-hzi.de

Genome-based resistance prediction of Mycobacterium tuberculosis for individualized treatment of multidrug resistant tuberculosis patients
Patrick Beckert, pbeckert@fz-borstel.de

German Center for Infection Research
Timo Jäger, timo.jaeger@dzif.de,
Elisa Reimer, elisa.reimer@dzif.de

Infectognostics Research Campus Jena

Virulence patterns of Staphylococcus aureus strains
Stefanie Deinhardt-Emmer
stefanie.deinhardt-emmer@med.uni-jena.de

Polyester-based nanoparticles to overcome the obstacles of mucus and biofilms under static and dynamic fluidic conditions
Mareike Klinger-Strobel
mareike.klinger-strobel@med.uni-jena.de

Carbonmonoxid releasing nanofibers as a potential anti-biofilm treatment
Mareike Klinger-Strobel
mareike.klinger-strobel@med.uni-jena.de

Multi-resistant Gram-negative bacteria: β-lactamases as target for rapid diagnostics
Oliwia Makarewicz
oliwia.makarewicz@med.uni-jena.de

Innovative tools for fast clinical diagnosis using Raman spectroscopy
Karina Weber
karina.weber@leibniz-ipht.de

Fast antibiotic susceptibility testing using Raman spectroscopy within microfluidic chips
Astrid Tannert
astrid.tannert@student.hu-berlin.de

Cold atmospheric pressure plasma as antimicrobial and its possibilities of “on spot” delivery
Torsten Gerling
gerling@inp-greifswald.de

SMEs

A novel peptide-based therapy to fight respiratory infections
Martin van Eijk
m.vaneijk@pepbiotics.com

Epitope mapping workflow for vaccine develoment combining computational analyses of the pathogen genome to the PepID biopeptides expression technology
Hubert Bernauer
info@atgbiosynthetics

Development of metallo-ß-lactamase inhibitors for combination treatment of carbapenem resistant Enterobacteriaceae
Martin Everett, Marc Lemonnier
martin.everett@antabio.com

MORE THAN SWEETS

glyconet Berlin Brandenburg

The platform
to interlink,
to cooperate,
to innovate,
to strengthen and
to visualize regional expertise
in glycosciences and glycobiotech.

JOIN US ON THE JOURNEY OF
GLYCOSCIENCES

Meet glycobiology in:
Diagnostics · Biopharmaceuticals · Vaccines ·
Nanotechnology · Bioinformatics ·
Probiotics · Microorganisms · Cosmetics

glyconet BERLIN BRANDENBURG

Fraunhofer IZI-BB

BEUTH HOCHSCHULE FÜR TECHNIK BERLIN University of Applied Sciences

Fraunhofer IAP

RWTH AACHEN UNIVERSITY

CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN

Technische Hochschule Wildau [FH] Technical University of Applied Sciences

GLYCOTOPE

biotechrabbit leap and lead

evoXX a division of advanced enzymes

FMP Leibniz Forschungsinstitut für Molekulare Pharmakologie

GALAB Laboratories

glyXera GmbH

HealthTwiSt Data Science as a Service

hybroTec

MicroDiscovery

PlasmaChem

scienova™ Innovating for better science

scienion ENABLING LIFE SCIENCE

UGA Biopharma

Wirtschaftsförderung Brandenburg | WFBB Standort. Unternehmen. Menschen.

Berlin Partner for Business and Technology

HealthCapital BERLIN BRANDENBURG

glyconet Berlin Brandenburg e.V.

Science Campus Golm
Am Mühenberg 13
14476 Potsdam, Germany

www www.glyconet.de
✉ info@glyconet.de
✆ +49 (0)331 979 219 72

Participants

(as of 26 February 2018)

No.	Name	Surname	Position	Company	CC
1	Frank	**Apostel**	Vice President Companion Diagnostics	R-Biopharm AG	DE
2	Christine	**Ardal**	Senior Advisor	Norwegian Institute of Public Health	NO
3	Till	**Bachmann**	Deputy Head of Division of Infection and Pathway Medicine	University of Edinburgh	GB
4	Niv	**Bachnoff**	CSO	Omnix Medical	IL
5	Susanne M.	**Bailer**	Group Manager Infection Biology and Array Technologies	Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB	DE
6	Renate	**Baker**	Europe Account Manager	Collaborative Drug Discovery	GB
7	Andreas A.	**Bastian**	CEO	AGILeBiotics B.V.	NL
8	Maria	**Bastian**	CSO	AGILeBiotics B.V	NL
9	Alexandre	**Batch**	Global Business Development & Entrepreneurship Leader	Institut Pasteur	FR
10	Jochen	**Bauer**	Vice President Development Wound Care	Paul Hartmann AG	DE
11	Patrick	**Beckert**	Doctoral Student	Research Center Borstel	DE
12	Lüder	**Behrens**	European Patent and Trade Mark Attorney	Boehmert & Boehmert	DE
13	Alexander	**Belcredi**	Managing Director | CEO	PhagoMed Biopharma GmbH	AT
14	Thierry	**Bernardi**	CEO	BioFilm Pharma	FR
15	Hubert S.	**Bernauer**	CEO	ATG:biosynthetics GmbH	DE
16	Henri-François	**Boedt**	Senior Loan Officer, Growth Capital and Innovation Finance	European Investment Bank	LU
17	Catharina	**Boehme**	CEO	FIND Diagnostics	CH
18	Katja	**Boelcker**	Project Manager	BIOCOM AG	DE
19	Stephan	**Breitfeld**	Managing Director DACH	ingeniam	DE
20	Andreas	**Buehler**		Resistell	DE
21	Michael	**Burnet**	CEO	Synovo GmbH	DE
22	Ines-Regina	**Buth**	Managing Partner	akampion	DE
23	Wojciech	**Chomicki**		Resistell	DE
24	Danuta	**Cichocka**	CEO	Resistell	CH
25	Moshik	**Cohen-Kutner**	CEO	Omnix Medical	IL
26	Emmanuelle	**Coutanceau**	Partner	Novo Holdings	DE
27	Delphine	**Croisier**	CEO	VIVEXIA	FR
28	Ingo	**Curdt**	Head of New Biomarker Research	Thermo Fisher Scientific	DE
29	Glenn	**Dale**	Head of Antibiotic Research and Earlies Development	Polyphor	CH
30	Pierre	**Daram**	Global Project Leader	Debiopharm International S.A.	CH
31	Michael	**de Baar**	Executive Director, Business Development & Licensing	MSD	GB
32	Leonie	**de Best**	CBO	Madam Therapeutics BV	NL
33	Cees	**de Joncheere**	Chair NADP	Netherlands Antibiotics Development Platform	NL
34	Stefanie	**Deinhardt-Emmer**	Research Assistant	Jena University Hospital	DE
35	Guennaëlle	**Dieppois**	Senior Scientist Antimicrobial Development	Debiopharm International S.A.	CH
36	Christian	**Döring**	Scientific Communication	Leibniz Health Technologies	DE
37	Sebastian	**Dümcke**		Uniklinik Köln	DE
38	Eva	**Ehrentreich-Förster**	Head of Department for Molecular Bioanalytics & Head of Microarray and Sensor Technology Unit	Fraunhofer Institute for Cell Therapy and Immunology	DE

No.	Name	Surname	Position	Company	CC
39	Ralf	**Ehricht**	Senior Principal Scientist Feasibility Studies	Abbott (Alere Technologies GmbH)	DE
40	Frank	**Emmrich**	Director	Fraunhofer Institute for Cell Therapy and Immunology (IZI)	DE
41	Martin	**Empting**	PostDoc	Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)	DE
42	Anne	**Endmann**	Consultant	VDI/VDE Innovation + Technik GmbH	DE
43	Aleks	**Engel**	Partner Novo Seeds and Director Repair Impact Fund	Novo Holdings A/S	DK
44	Markus	**Engelhard**	European Patent and Trade Mark Attorney	Boehmert & Boehmert	DE
45	Martin	**Everett**	CSO	Antabio	FR
46	Guy-Charles	**Fanneau de La Horie**	CEO	Pherecydes Pharma	FR
47	Catherine	**Featherston**	Journalist	APM Health Europe	DE
48	James David	**Findlay**		Morton Findlay Associates Ltd	GB
49	Terry	**Finn**	Discovery Project Leader	Debiopharm International S.A.	CH
50	Miriam	**Fürst-Wilmes**	Scientist	Federal Institute for Drugs and Medical Devices (BfArM)	DE
51	Marcus	**Furch**	CEO	Rodos BioTarget GmbH	DE
52	Jérôme	**Gabard**	COO	Pherecydes Pharma	FR
53	Markus	**Gerhard**	CSO	ImevaX GmbH	DE
54	Torsten	**Gerling**	Research Group Leader “Plasma Source Concepts”	INP Greifswald e.V. – Leibniz-Institute for Plasma Science and Technology	DE
55	Marc	**Gitzinger**	CEO & Co-Founder	BioVersys AG	CH
56	Philippe	**Glaser**	Head of the Ecology and Evolution of Antibiotic Resistance Unit	Institut Pasteur	FR
57	Grzegorz	**Gonciarz**	Partner	Resistell	CH
58	Herman	**Goossens**	Head of LMM Vaccine & Infectious Disease Institute	University of Antwerp	BE
59	Jan	**Gradel**	Director Business Development	Sino German Hi Tech Park	DE
60	Sibylla	**Grahn**	European Patent and Trade Mark Attorney	Boehmert & Boehmert	DE
61	Michael	**Graz**	Managing Director	Neem Biotech	GB
62	Martin	**Griessl**	Deputy Director R&D, Head of Protein Design	Lisando GmbH	DE
63	George	**Griffin**	Chair of fund SAB	St George’s, University of London	GB
64	Thomas	**Grunwald**	Head of Preclinical Validation Unit	Fraunhofer Institute for Cell Therapy and Immunology	DE
65	Ibrahima	**Guillard**	Account Manager	Mutabilis	FR
66	Sigrun	**Hähnel**	Manager Innovations	ESA – Patentverwertungsagentur Sachsen-Anhalt GmbH	DE
67	Sascha	**Hartmann**	Business Development Executive	Concept Life Sciences	GB
68	Michael	**Hausmann**	Director R&D | Clinical Diagnostics Biomarkers	Thermo Fisher Scientific	DE
69	Sabina	**Heim**	Senior Technology Manager	Ascenion GmbH	DE
70	Jutta	**Heim**	Chair of Scientific Advisory Committee	GARDP	CH
71	Dirk	**Heinz**	Scientific Director	Helmholtz Centre for Infection Research	DE
72	Jens	**Hellwage**	CEO	InfectoGnostics Research Campus Jena	DE
73	Jürgen	**Hemberger**		Technische Hochschule Mittelhessen (THM)	DE
74	Thomas	**Hesterkamp**	Head Translational Project Management	German Center for Infection Research, Helmholtz Centre for Infection Researach	DE

No.	Name	Surname	Position	Company	CC
75	Cornelia	**Hettrich**	Researcher: Susceptibility testing and artificial binders	Fraunhofer Institute for Cell Therapy and Immunology	DE
76	Achim	**Hoerauf**	Director	Institute of Medical Parasitology	DE
77	Hans Christian	**Holländer**	Senior Business Developer	Technical University of Denmark	DK
78	Uta	**Holmer**	Eventmanager	BIOCOM AG	DE
79	Chris	**Howie**	Life Science Specialist – Europe	UK's Department for International Trade	DE
80	Juan José	**Infante Viñolo**	CEO & Co-Founder	Vaxdyn	ES
81	Peter	**Jackson**	Executive Director	AMR Centre Ltd	GB
82	Timo	**Jäger**	Managing Director	German Center for Infection Research - DZIF	DE
83	Mark	**Jones**	Head of Project Management and Head of PreClinical Development	Basilea Pharmaceutica Ltd.	CH
84	Françoise	**Jung**	Project Manager	Polyphor	DE
85	Michael	**Kahnert**	Corporate Counsel	BIO Deutschland e.V.	DE
86	Frank	**Kalkbrenner**	Vice President Boehringer Ingelheim Venture Fund	Boehringer Ingelheim GmbH	DE
87	Ulrike	**Kaltenhauser**	Managing Director	BioSysNet	DE
88	Anders	**Karlén**	Professor in Computer-Aided Drug Design	Uppsala University	SE
89	Philip	**Kemp**	Director of Special Projects	Destiny Pharma Ltd	GB
90	Helmut	**Kessmann**	Head Business Development	Polyphor	CH
91	Ute	**Kilger**	Partner	Boehmert & Boehmert	DE
92	Mareike	**Klinger-Strobel**	Research Assistant	Jena University Hospital	DE
93	Josefien	**Knoeff**	Researcher	Access to Medicine Foundation	NL
94	Anke	**Kopacek**	Network Management	DiagnostikNet-BB	DE
95	Schelto	**Korf**	Alliance Manager	Immuno Valley / Netherlands Antibiotic Development Platform	NL
96	Ulrich	**Koszinowski**	Vice President Clinical Development	HYpharm GmbH	DE
97	Stefan	**Kubick**	Head of Cell-free Protein Synthesis Unit	Fraunhofer Institute for Cell Therapy and Immunology (IZI)	DE
98	Frédéric	**Lajaunias**	Director	Combioxin SA	CH
99	Marc	**Lemonnier**	CEO	Antabio	FR
100	Lisette	**Leonhardt**	Consultant	VDI/VDE Innovation + Technik GmbH	DE
101	Anastasia	**Liapis**	Market Development Manager	GNA Biosolutions GmbH	DE
102	Derek	**Lindsay**	COO	AMR Centre Ltd	GB
103	Zoltán	**Magyarics**	Director of Early Clinical Development	Arsanis Biosciences GmbH	AT
104	Oliwia	**Makarewicz**	Head of Laboratory	Jena University Hoepital	DE
105	Davide	**Manissero**	Senior Director, Infectious Diseases	SHIONOGI Ltd	GB
106	Boris	**Mannhardt**	CEO	BIOCOM AG	DE
107	Jessica	**Manthey**	Investment Promotion Manager	Flanders Invest & Trade	DE
108	Stefan	**Margraf**	Research Assistant	Fraunhofer Institute for Cell Therapy and Immunology	DE
109	Daniel	**Mark**	CEO	SpinDiag GmbH	DE
110	Diana	**Martens**		R-Biopharm AG	DE
111	Kai	**Masur**	Head of Associated Research Group "Plasma Wound Healing"	Leibniz Institue for Plasma Science and Technology	DE
112	Hannelore	**Meyer**	Group Leader	Technische Universität München	DE
113	Marcus	**Miethke**	Project Manager	Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)	DE
114	Ajay	**Mistry**	CEO & Co-Founder	Oppilotech Ltd	GB
115	Sonja	**Molinaro**	CEO	HYpharm GmbH	DE
116	Søren	**Møller**	Managing Partner	Novo Seeds	DK

No.	Name	Surname	Position	Company	CC
117	Johan	**Mouton**	Chair, National AST	EUCAST	SE
118	Rolf	**Müller**	Managing Director	Helmholtz Institute for Pharmaceutical Research (HIPS)	DE
119	Svetlana	**Neubauer**	PostDoc	Jena University Hospital	DE
120	Jennifer	**Oduro**		preclinics GmbH	DE
121	Kemi	**Olatunde**	Marketing Manager	Tunadel Medical Tours Ltd.	NG
122	António	**Ornelas Soares**	Executive Board Member, Strategic Alliances	FASTinov	PT
123	Kevin	**Outterson**	Executive Director	CARB-X	US
124	Kfir	**Oved**	CTO & Co-Founder	MeMed Diagnostics, Ltd, Israel	IL
125	Jean-Pierre	**Paccaud**	Director of Business Development and Corporate Strategy	Global Antibiotic R&D Partnership (GARDP)	CH
126	Christophe	**Parsy**	Pharmaceutical Program Director	Deinove SA	FR
127	Sarah	**Paulin**	Technical Officer Innovation, Access & Use	World Health Organization	CH
128	Lloyd	**Payne**	Member of fund SAB	Evotec	DE
129	Marie	**Petit**	BEAM Coordinator	Villiger Valuation – Bout d'Ouchée Sàrl	CH
130	Kenneth	**Pfarr**	Group Leader	Institute for Medical Microbiology, Immunology and Parasitology	DE
131	Jean-Jacques	**Pierrat**	Embassy Counsellor for Science and Technology	French Embassy in Berlin	DE
132	Cidália	**Pina-Vaz**	CEO & Co-Founder	FASTinov	PT
133	Alessandro	**Pini**	CEO	SetLance srl	IT
134	Achim	**Plum**	CBO	Curetis N.V.	AT
135	Jürgen	**Popp**	Scientific Director	Leibniz Institute of Photonic Technologies	DE
136	Andreas	**Posch**	Managing Director	Ares Genetics	AT
137	Rachel	**Postert**	Senior Business Development Manager	UK´s Department for International Trade	DE
138	Elisa	**Reimer**	Scientific Officer	German Center for Infection Research	DE
139	Antje	**Rötger**	CEO	Carpegen GmbH	DE
140	Katharina	**Rox**	PostDoc	Helmholtz Centre for Infection Research	DE
141	Friederike	**Saathoff**	Project Coordinator – Hygiene and Infection Network	Life Science Nord Management GmbH	DE
142	Jakub	**Sadílek**	Projectmanager	MediTox s.r.o.	CZ
143	Annette	**Säfholm**	CEO	Gedea Biotech AB	SE
144	Bruce	**Savage**	CEO	GFC Diagnostics Ltd	GB
145	Andrea	**Schiefer**	PostDoc	Institute for Medical Microbiology, Immunology and Parasitology	DE
146	Steven	**Schmitt**	Postdoctoral Researcher	ETH Zürich	CH
147	Holger	**Schmoll**	CFO	AiCuris Anti-infective Cures GmbH	DE
148	Oliver	**Schnell**	Head of Marketing	BIOCOM AG	DE
149	Florence	**Séjourné**	CEO	Da Volterra	FR
150	Pablo	**Serrano**	Head of Innovation & Research/ Biotechnology	Bundesverband der Pharmazeutischen Industrie e.V. (BPI)	DE
151	Andrew	**Shearer**	Business Liaison Manager	Neem Biotech	GB
152	Andrea	**Spelberg**	Head of Research for Global Health Unit	Federal Ministry of Education and Research	DE
153	Christoph	**Spennemann**	Legal Officer and Officer-in-Charge	UNCTAD	CH
154	Silke	**Stahlberg**	Managing Director	Centra BioHub GmbH	DE
155	Maria	**Stasinou**	Researcher	Access to Medicine Foundation	NL
156	Liana	**Steeghs**	Managing Director	Immuno Valley	NL
157	Beat	**Steffen**	Principal	Novartis Venture Fund	CH

No.	Name	Surname	Position	Company	CC
158	Helena	**Strevens**	Consultant Obstetrician Skane University Hospital	Gedea Biotech AB	SE
159	Gerhard	**Stumm**		VDI Technologiezentrum GmbH	DE
160	Petar	**Stupar**		Resistell	DE
161	Sigrun	**Szepanski**	Technology Manager Berlin Health Innovations	Berlin Instiute of Health (BIH)	DE
162	Pierre	**Tangermann**	Head of BD and Marketing	Fraunhofer Institute for Cell Therapy and Immunology	DE
163	Astrid	**Tannert**	PostDoc	Leibniz Institute of photonioc technology	DE
164	Gerd	**Teisslinger**	Executive Institute Management	Fraunhofer Institute for Molecular Biology & Applied Ecology	DE
165	Nicolas	**Tesse**	Scientific Director	Neteos Groupe	FR
166	Luigi	**Toti**	Group Leader	Sanofi-Aventis Deutschland GmbH	DE
167	M. Ya ız	**Ünver**	Research Scientist	AGILeBiotics B.V.	NL
168	Lars	**Ullerich**	Managing Director-Business Development	GNA Biosolutions GmbH	DE
169	Maarten	**van Dongen**	Founder	AMR INSIGHTS	NL
170	Martin	**van Eijk**	Entrepeneur / Postdoctoral researcher	PepBiotics B.V. / Utrecht University	NL
171	Remko	**van Leeuwen**	CEO	Madam Therapeutics BV	NL
172	Mariana	**Vaschetto**	Head of European Operations	Collaborative Drug Discovery	GB
173	Per	**Venge**	Professor in Clinical Chemistry	Uppsala University	SE
174	Andreas	**Vilcinskas**	Location Head Gießen, Business Fields Bioresources	Fraunhofer Institute for Molecular Biology and Applied Ecology IME	DE
175	Jorge	**Villacian**	Chief Medical Officer	Janssen Diagnostics, Johnson & Johnson	BE
176	Philippe	**Villain-Guillot**	President	Nosopharm SAS	FR
177	Laura	**Voisin**	Scientific Department for Health and Biotechnology	French Embassy in Berlin	DE
178	Markus	**von Nickisch-Rosenegk**	Head of Molecular Bio-Engineering Unit	Fraunhofer Institute for Cell Therapy and Immunology	DE
179	Ralf	**Warrass**	Director	MSD AH Innovation GmbH	DE
180	Jan	**Wauters**	Science and Technology Counselor Life Sciences and Nanotechnologies	Flanders Investment and TradeConsulate General of Belgium– Flanders Investment & Trade	US
181	Karina	**Weber**	Head of young reseach group	Leibniz-Institut für Photonische Technologien e.V.	DE
182	Christin	**Weber**	Consultant	InfectoGnostics Research Campus Jena	DE
183	Ludger	**Weß**	Managing Partner	akampion	DE
184	Andrea	**Wetzel**	Ass. Head of Central Office	Fraunhofer Group for Life Sciences	DE
185	Laurie	**Williams**	Business Development Manager	Department for International Trade Consulate General	DE
186	Mathias	**Winterhalter**	ND4BB-Translocation	Jacobs University Bremen gGmbH	DE
187	Sandra	**Wirsching**	Divisional Director	BIOCOM AG	DE
188	Sabine	**Wronski**	Group Manager	Fraunhofer Institute for Toxicology and Experimental Medicine ITEM	DE
189	Irene	**Wüthrich**	PostDoc	ETH Zürich	CH
190	Hans-Joachim	**Zeiler**	CEO	Creative-Therapeutics GmbH	DE
191	Ghada	**Zoubiane**	Science Lead, Drug-Resistant Infections	Wellcome Trust	GB

Noval Antimicrobials and AMR Diagnostics

Contact and further information:

BIOCOM AG

Lützowstrasse 33–36
10785 Berlin / Germany

Tel.: +49-30-26 49 21-0
Fax: +49-30-26 49 21-11

events@biocom.de
www.biocom.de